Aurinia Pharmaceuticals (AUPH) Liabilities and Shareholders Equity (2019 - 2026)

Aurinia Pharmaceuticals has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $724.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 43.41% year-over-year to $724.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.5 billion (up 17.73% YoY), and the FY2025 full-year result was $751.6 million, up 36.49% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $724.0 million, down from $751.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $751.6 million in Q4 2025, with the low at $451.8 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $541.3 million across 5 years, with a median of $523.5 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity dropped 13.34% — and 2026, when it soared 43.41%.
• Aurinia Pharmaceuticals' Liabilities and Shareholders Equity stood at $470.9 million in 2022, then climbed by 16.4% to $548.1 million in 2023, then advanced by 0.47% to $550.6 million in 2024, then jumped by 36.49% to $751.6 million in 2025, then retreated by 3.67% to $724.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $724.0 million (Q1 2026), $751.6 million (Q4 2025), and $527.5 million (Q3 2025), per Business Quant data.